<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899197</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000547204</org_study_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU-74B07</secondary_id>
    <secondary_id>CCCWFU-IRB00002657</secondary_id>
    <nct_id>NCT00899197</nct_id>
  </id_info>
  <brief_title>Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer</brief_title>
  <official_title>Tamoxifen Resistance in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may&#xD;
      help doctors identify and learn more about biomarkers related to tamoxifen resistance.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I,&#xD;
      stage II, stage IIIA, or stage IIIB breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify women who are resistant to tamoxifen citrate and other drugs for the treatment&#xD;
           of breast cancer by testing their plasma for the presence of proteins (e.g., macrophage&#xD;
           migration inhibition factor) encoded by resistance-inducing genes (RIGs).&#xD;
&#xD;
        -  Provide retrospective data on the predictive value of RIGs to serve as the basis for a&#xD;
           prospective clinical trial of these genes as predictors of drug resistance.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to response during&#xD;
      tamoxifen citrate (TAM) therapy (resistant group [i.e., those who develop recurrent breast&#xD;
      cancer while being treated with TAM] vs conditionally sensitive group [i.e., those who have&#xD;
      disease-free survival for over 3 years after initial diagnosis while being treated with&#xD;
      TAM]).&#xD;
&#xD;
      Patients undergo blood collection at baseline, within 3 weeks of initiation of TAM therapy,&#xD;
      and then every 6 months for 3 years or until relapse, whichever comes first. Samples are&#xD;
      analyzed by enzyme-linked immunosorbent assay for expression of protein biomarkers (i.e.,&#xD;
      kallikrein gene 10, macrophage migration inhibition factor, prolyl carboxypeptidase, queuine&#xD;
      tRNA-ribosyltransferase, and kinesin) encoded by resistance-inducing genes. An additional&#xD;
      blood sample is obtained from patients at the time of relapse, if available.&#xD;
&#xD;
      Patients also undergo assessment of medical history, personal habits, and characteristics of&#xD;
      breast cancer (e.g., tumor histology, stage, and grade) at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the mechanisms of tamoxifen citrate (TAM) resistance in breast cancer</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expression levels of protein biomarkers of TAM resistance as measured periodically for 3 years or until relapse, whichever comes first</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective data on the predictive value of resistance-inducing genes</measure>
  </primary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female &gt;/= 18 years old with confirmed invasive breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Initial pathologic stage I-IIIB disease&#xD;
&#xD;
               -  No stage IV disease&#xD;
&#xD;
          -  Meets the following criteria for breast cancer therapy:&#xD;
&#xD;
               -  Received prior primary local therapy for breast cancer&#xD;
&#xD;
               -  Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within&#xD;
                  3 weeks&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen-receptor positive tumor&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Pre- or post-menopausal&#xD;
&#xD;
          -  Must be able to donate 20 mL of blood&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe anemia, defined as hemoglobin &lt; 11 g/dL&#xD;
&#xD;
          -  Psychiatric history that would preclude obtaining informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Akman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

